MX2020005430A - Ligandos de psma para la formacion de imagenes y endorradioterapia. - Google Patents

Ligandos de psma para la formacion de imagenes y endorradioterapia.

Info

Publication number
MX2020005430A
MX2020005430A MX2020005430A MX2020005430A MX2020005430A MX 2020005430 A MX2020005430 A MX 2020005430A MX 2020005430 A MX2020005430 A MX 2020005430A MX 2020005430 A MX2020005430 A MX 2020005430A MX 2020005430 A MX2020005430 A MX 2020005430A
Authority
MX
Mexico
Prior art keywords
endoradiotherapy
imaging
psma
psma ligands
compounds
Prior art date
Application number
MX2020005430A
Other languages
English (en)
Inventor
Wester Hans Jürgen
Alexander Schmidt
Mara Parzinger
Original Assignee
Univ Muenchen Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen Tech filed Critical Univ Muenchen Tech
Publication of MX2020005430A publication Critical patent/MX2020005430A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nuclear Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgación se refiere a la formación de imágenes y endorradioterapia de enfermedades que implican antígeno de membrana específico de próstata (PSMA). Se proporcionan compuestos que unen o inhiben PSMA y adicionalmente llevan al menos una fracción que es susceptible de radiomarcaje. También se porporcionan usos médicos de dichos compuestos.
MX2020005430A 2017-12-11 2018-12-11 Ligandos de psma para la formacion de imagenes y endorradioterapia. MX2020005430A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17206510 2017-12-11
PCT/EP2018/084399 WO2019115547A1 (en) 2017-12-11 2018-12-11 Psma ligands for imaging and endoradiotherapy

Publications (1)

Publication Number Publication Date
MX2020005430A true MX2020005430A (es) 2020-08-27

Family

ID=60654872

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020005430A MX2020005430A (es) 2017-12-11 2018-12-11 Ligandos de psma para la formacion de imagenes y endorradioterapia.
MX2023005053A MX2023005053A (es) 2017-12-11 2020-07-13 Ligandos de psma para la formacion de imagenes y endorradioterapia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023005053A MX2023005053A (es) 2017-12-11 2020-07-13 Ligandos de psma para la formacion de imagenes y endorradioterapia.

Country Status (30)

Country Link
US (2) US11497819B2 (es)
EP (2) EP3723815B1 (es)
JP (1) JP7317375B2 (es)
KR (1) KR20200097690A (es)
CN (2) CN111182927B (es)
AU (1) AU2018382479A1 (es)
BR (1) BR112020011727A2 (es)
CA (1) CA3078104A1 (es)
CL (1) CL2020001542A1 (es)
CR (1) CR20200241A (es)
CU (1) CU24677B1 (es)
DK (2) DK3723815T3 (es)
EC (1) ECSP20029142A (es)
ES (1) ES2914832T3 (es)
HR (1) HRP20220764T1 (es)
HU (1) HUE059083T2 (es)
IL (2) IL274072B1 (es)
JO (1) JOP20200135A1 (es)
LT (1) LT3723815T (es)
MX (2) MX2020005430A (es)
PE (1) PE20210456A1 (es)
PL (1) PL3723815T3 (es)
PT (1) PT3723815T (es)
RS (1) RS63279B1 (es)
SG (1) SG11202002965WA (es)
SI (1) SI3723815T1 (es)
TN (1) TN2020000072A1 (es)
UA (1) UA126413C2 (es)
WO (1) WO2019115547A1 (es)
ZA (1) ZA202003472B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA126413C2 (uk) 2017-12-11 2022-09-28 Техніше Універзітет Мюнхен Ліганди psma для візуалізації та ендорадіотерапії
PL3917626T3 (pl) * 2019-01-30 2023-11-27 Technische Universität München Dwutrybowy radioznacznik i terapeutyk wiążący psma
IL303420A (en) * 2019-01-30 2023-08-01 Univ Muenchen Tech Diagnostic imaging materials for cancer
WO2020252598A1 (en) 2019-06-21 2020-12-24 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
CN112321673B (zh) * 2020-11-04 2022-09-20 北京市肿瘤防治研究所 一种前列腺特异性膜抗原靶向抑制剂及应用和探针
CN113354707A (zh) * 2021-06-07 2021-09-07 苏州思萃同位素技术研究所有限公司 一种针对前列腺癌的三功能诊疗一体化药物前体的合成方法及其产品
WO2023173074A2 (en) * 2022-03-10 2023-09-14 The Research Foundation For The State University Of New York Immunostimulant-cytotoxic conjugate composition and methods for cancer treatment
CN115010629B (zh) * 2022-06-07 2024-02-23 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057023A1 (es) 2005-05-16 2007-11-14 Gilead Sciences Inc Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
CN107382846B (zh) * 2008-08-01 2021-07-06 约翰.霍普金斯大学 Psma-结合剂及其用途
WO2010135431A2 (en) * 2009-05-19 2010-11-25 The Regents Of The University Of California Compositions, devices, and methods related to prostate-specific membrane antigen
DE202014011600U1 (de) * 2013-10-18 2023-05-31 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Markierte Inhibitoren des prostataspezifischen Membranantigens (PSMA), deren Verwendung als bildgebende Mittel und pharmazeutische Wirkstoffe für die Behandlung von Prostatakrebs
US10683272B2 (en) * 2014-05-06 2020-06-16 The Johns Hopkins University Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy
US10688200B2 (en) 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
CN114716387A (zh) * 2016-03-22 2022-07-08 约翰霍普金斯大学 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
TW201930265A (zh) 2017-12-11 2019-08-01 西班牙商阿爾米雷爾有限公司 作為acc抑制劑的吡咯衍生物
BR112020010803A2 (pt) 2017-12-11 2020-11-10 Helsinn Healthcare Sa sal, (r)-3-(1-(2,3-dicloro-4-(pirazin-2-il)fenil)-2,2,2-trifluoroetil)-1-metil-1-(1-metilpiperidin-4-il) uréia cristalino, produto de medicamento, composição, método para preparar o sal e usos do sal
UA126413C2 (uk) 2017-12-11 2022-09-28 Техніше Універзітет Мюнхен Ліганди psma для візуалізації та ендорадіотерапії

Also Published As

Publication number Publication date
IL274072B1 (en) 2024-07-01
IL313103A (en) 2024-07-01
EP4008359A1 (en) 2022-06-08
HRP20220764T1 (hr) 2022-09-16
TN2020000072A1 (en) 2022-01-06
EP3723815A1 (en) 2020-10-21
US20230122957A1 (en) 2023-04-20
PE20210456A1 (es) 2021-03-08
CR20200241A (es) 2020-09-21
CA3078104A1 (en) 2019-06-20
CU24677B1 (es) 2023-09-07
CL2020001542A1 (es) 2020-10-02
US20200297876A1 (en) 2020-09-24
ZA202003472B (en) 2022-06-29
LT3723815T (lt) 2022-07-25
SI3723815T1 (sl) 2022-07-29
UA126413C2 (uk) 2022-09-28
IL274072A (en) 2020-06-30
CU20200052A7 (es) 2021-03-11
CN111182927A (zh) 2020-05-19
RU2020116158A (ru) 2022-01-13
WO2019115547A1 (en) 2019-06-20
DK3723815T3 (da) 2022-07-11
CN116617421A (zh) 2023-08-22
EP3723815B1 (en) 2022-04-20
US11497819B2 (en) 2022-11-15
MX2023005053A (es) 2023-05-17
DK4008359T3 (da) 2024-10-14
JOP20200135A1 (ar) 2020-06-02
HUE059083T2 (hu) 2022-10-28
JP2021505532A (ja) 2021-02-18
CN111182927B (zh) 2023-07-21
JP7317375B2 (ja) 2023-07-31
ECSP20029142A (es) 2020-09-30
KR20200097690A (ko) 2020-08-19
ES2914832T3 (es) 2022-06-16
SG11202002965WA (en) 2020-04-29
PT3723815T (pt) 2022-05-30
JP2023139063A (ja) 2023-10-03
AU2018382479A1 (en) 2020-04-16
BR112020011727A2 (pt) 2020-11-17
EP4008359B1 (en) 2024-09-11
RS63279B1 (sr) 2022-06-30
PL3723815T3 (pl) 2022-07-18

Similar Documents

Publication Publication Date Title
MX2023005053A (es) Ligandos de psma para la formacion de imagenes y endorradioterapia.
ZA201906832B (en) Novel psma-binding agents and uses thereof
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201691857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
MX2017016611A (es) Moduladores de tgr5 y metodos de uso de los mismos.
EA201892430A1 (ru) Синтез индазолов
UY36757A (es) Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
PH12020551443A1 (en) Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
EA201691323A1 (ru) Анти-vista антитела и фрагменты
TR201909093T4 (tr) Hidroksi içeren FXR (NR1H4) modüle edici bileşikleri.
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201691487A1 (ru) Антитела человека к pd-l1
MA34057B1 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
EP3700917A4 (en) NEW RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANARY ANTIGEN
WO2015054642A3 (en) Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy
EA201692100A8 (ru) Новые антитела против rnf43 и способы их применения
EA201691541A1 (ru) Новые анти-baff антитела
MA38986A3 (fr) Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
EA201691141A1 (ru) Соединения против ccr6
GEP20207106B (en) 18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
EA201992317A1 (ru) Композиции и способы для диагностики рака легких